Literature DB >> 25752817

Nanotechnology in the management of cervical cancer.

Jiezhong Chen1, Wenyi Gu, Lei Yang, Chen Chen, Renfu Shao, Kewei Xu, Zhi Ping Xu.   

Abstract

Cervical cancer is a major disease with high mortality. All cervical cancers are caused by infection with human papillomaviruses (HPV). Although preventive vaccines for cervical cancer are successful, treatment of cervical cancer is far less satisfactory because of multidrug resistance and side effects. In this review, we summarize the recent application of nanotechnology to the diagnosis and treatment of cervical cancer as well as the development of HPV vaccines. Early detection of cervical cancer enables tumours to be efficiently removed by surgical procedures, leading to increased survival rate. The current method of detecting cervical cancer by Pap smear can only achieve 50% sensitivity, whereas nanotechnology has been used to detect HPVs with greatly improved sensitivity. In cervical cancer treatment, nanotechnology has been used for the delivery of anticancer drugs to increase treatment efficacy and decrease side effects. Nanodelivery of HPV preventive and therapeutic vaccines has also been investigated to increase vaccine efficacy. Overall, these developments suggest that nanoparticle-based vaccine may become the most effective way to prevent and treat cervical cancer, assisted or combined with some other nanotechnology-based therapy.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 25752817     DOI: 10.1002/rmv.1825

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  14 in total

1.  MicroRNAs, signaling pathways and diseases.

Authors:  Jiezhong Chen
Journal:  Ann Transl Med       Date:  2015-12

Review 2.  HPV-p53-miR-34a axis in HPV-associated cancers.

Authors:  Jiezhong Chen; Kong-Nan Zhao
Journal:  Ann Transl Med       Date:  2015-12

3.  Gold nanoparticle biodistribution in pregnant mice following intravenous administration varies with gestational age.

Authors:  N'Dea S Irvin-Choy; Katherine M Nelson; Megan N Dang; Jason P Gleghorn; Emily S Day
Journal:  Nanomedicine       Date:  2021-06-17       Impact factor: 6.096

4.  Enhanced uptake and transport of PLGA-modified nanoparticles in cervical cancer.

Authors:  Lee B Sims; Louis T Curtis; Hermann B Frieboes; Jill M Steinbach-Rankins
Journal:  J Nanobiotechnology       Date:  2016-04-22       Impact factor: 10.435

Review 5.  Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors.

Authors:  Bilal Zulfiqar; Amnah Mahroo; Kaenat Nasir; Rai Khalid Farooq; Nasir Jalal; Muhammad Usman Rashid; Kashif Asghar
Journal:  Onco Targets Ther       Date:  2017-01-21       Impact factor: 4.147

6.  Investigating core genetic-and-epigenetic cell cycle networks for stemness and carcinogenic mechanisms, and cancer drug design using big database mining and genome-wide next-generation sequencing data.

Authors:  Cheng-Wei Li; Bor-Sen Chen
Journal:  Cell Cycle       Date:  2016-06-13       Impact factor: 4.534

7.  Biodegradable andrographolide-eluting nanofibrous membranes for the treatment of cervical cancer.

Authors:  Yi-Pin Chen; Yen-Wei Liu; Demei Lee; Jiantai Timothy Qiu; Tzung-Yan Lee; Shih-Jung Liu
Journal:  Int J Nanomedicine       Date:  2019-01-09

8.  Ultrasound Microbubble-Mediated microRNA-505 Regulates Cervical Cancer Cell Growth via AKT2.

Authors:  Leilei Xu; Qin Zhang; Changhua Li; Fu Hua; Xiaoping Liu
Journal:  Anal Cell Pathol (Amst)       Date:  2020-10-15       Impact factor: 2.916

9.  29 immune-related genes pairs signature predict the prognosis of cervical cancer patients.

Authors:  Han Nie; Fanqin Bu; Jiasheng Xu; Taoshen Li; Jun Huang
Journal:  Sci Rep       Date:  2020-08-25       Impact factor: 4.379

10.  CdO nanoparticles, c-MWCNT nanoparticles and CdO nanoparticles/c-MWCNT nanocomposite fibres: in vitro assessment of anti-proliferative and apoptotic studies in HeLa cancer cell line.

Authors:  Jayaraman Saranya; Balakrishnapillai Suseela Sreeja; Gurunathan Padmalaya; Sankararajan Radha; Ponnusamy Senthil Kumar
Journal:  IET Nanobiotechnol       Date:  2020-10       Impact factor: 1.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.